Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 201

1.

A review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.

Maidment ID, Fox C, Boustani M.

Acta Psychiatr Scand. 2005 Jun;111(6):403-9. Review.

PMID:
15877706
2.

Cholinesterase inhibitors for Parkinson's disease dementia.

Maidment I, Fox C, Boustani M.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004747. Review.

PMID:
16437494
3.

[Dementia in Parkinson's disease].

Halvorsen Ø, Tysnes OB.

Tidsskr Nor Laegeforen. 2007 Oct 4;127(19):2517-20. Review. Norwegian.

4.

[Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors].

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D.

Nervenarzt. 2008 Jan;79(1):36-9, 42-6. Review. German.

PMID:
17687535
5.

Non-dopaminergic treatment of cognitive impairment and dementia in Parkinson's disease: a review.

Leroi I, Collins D, Marsh L.

J Neurol Sci. 2006 Oct 25;248(1-2):104-14. Epub 2006 Jun 27. Review.

PMID:
16806271
6.

A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.

Thomas AJ, Burn DJ, Rowan EN, Littlewood E, Newby J, Cousins D, Pakrasi S, Richardson J, Sanders J, McKeith IG.

Int J Geriatr Psychiatry. 2005 Oct;20(10):938-44.

PMID:
16163744
7.

Treatment of dementia associated with Parkinson's disease.

Emre M.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S457-61. doi: 10.1016/S1353-8020(08)70049-X. Review.

PMID:
18267283
8.

Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.

Wesnes K.

Drugs Today (Barc). 2007 Jun;43(6):349-59. Review.

PMID:
17612707
9.

Rivastigmine in Parkinson's disease dementia.

Chitnis S, Rao J.

Expert Opin Drug Metab Toxicol. 2009 Aug;5(8):941-55. doi: 10.1517/17425250903105420. Review.

PMID:
19619073
10.

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY.

Neurosci Behav Physiol. 2008 Nov;38(9):937-45. doi: 10.1007/s11055-008-9077-3.

PMID:
18975103
11.

[Acetylcholinesterase inhibitors for dementia--an update].

Anghelescu I, Heuser I.

MMW Fortschr Med. 2007 May 21;149 Suppl 2:76-8. Review. German.

PMID:
17724973
12.

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.

Aarsland D, Mosimann UP, McKeith IG.

J Geriatr Psychiatry Neurol. 2004 Sep;17(3):164-71. Review.

PMID:
15312280
13.

Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.

[No authors listed]

Prescrire Int. 2007 Oct;16(91):197-8.

PMID:
17926835
14.

Effectiveness of acetylcholinesterase inhibitors: diagnosis and severity as predictors of response in routine practice.

Van Der Putt R, Dineen C, Janes D, Series H, McShane R.

Int J Geriatr Psychiatry. 2006 Aug;21(8):755-60.

PMID:
16906631
15.

[Dementia in Parkinson's disease].

Caixeta L, Vieira RT.

Rev Bras Psiquiatr. 2008 Dec;30(4):375-83. Review. Portuguese.

16.

Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data.

van Laar T, De Deyn PP, Aarsland D, Barone P, Galvin JE.

CNS Neurosci Ther. 2011 Oct;17(5):428-41. doi: 10.1111/j.1755-5949.2010.00166.x. Epub 2010 Jul 7. Review.

PMID:
21951368
17.

[Diagnosis and clinical therapy for Parkinson's disease].

Wenzel S, Mollenhauer B, Trenkwalder C.

Nervenarzt. 2006 Dec;77(12):1439-43. Review. German.

PMID:
17093957
18.

Treatment of dementia: anything new?

Machado JC, Caramelli P.

Curr Opin Psychiatry. 2006 Nov;19(6):575-80. Review.

PMID:
17012934
19.

Rivastigmine: in Parkinson's disease dementia.

Siddiqui MA, Wagstaff AJ.

CNS Drugs. 2006;20(9):739-47; discussion 748-50. Review.

PMID:
16953649
20.

Treatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.

Liepelt I, Maetzler W, Blaicher HP, Gasser T, Berg D.

Dement Geriatr Cogn Disord. 2007;23(6):351-67. Epub 2007 Mar 26. Review.

Items per page

Supplemental Content

Write to the Help Desk